Molecular design and characterization of recombinant long half-life mutants of human tissue factor pathway inhibitor

Summary

Tissue factor pathway inhibitor (TFPI) is a physiological inhibitor of extrinsic pathway of coagulation and has biological functions of anticoagulation and anti-inflammation. Although TFPI has been proved to be a good therapeutic agent of sepsis, inflammatory shock, and DIC, the clinical application and therapeutic effects of TFPI are impeded because of its short half-life in vivo. In order to prolong the half-life of TFPI, homology modeling and molecule docking were performed on a computer workstation principally in protein structural biology and binding characteristics between TFPI and its receptor LRP (low-density lipoprotein receptor related protein). Two recombinant long half-life human TFPI mutants coined TFPI-Mut1 and TFPI-Mut4 were designed and expressed in E.coli. In comparison with the wild-type TFPI, TFPI-Mut1 and TFPI-Mut4 presented a few of changes in spatial configuration and a decrease in relative Gibbs free energy of docking complex by 17.3% and 21.5%, respectively, as indicated by a computer simulation. After refolding and purification, anticoagulant activities, anti-TF/FVIIa and anti-FXa activities of the mutants were found to be the same as those of wide-type TFPI. The pharmacokinetics research indicated that alpha phase half-life (t1/2α) of TFPI-Mut1 and TFPI-Mut4 were prolonged 1.33-fold and 1.96-fold respectively, beta phase half-life (t1/2 β) of TFPI-Mut1 and TFPI-Mut4 were prolonged 1.62-fold and 4.22-fold respectively. These results suggested that TFPI-Mut1 and TFPI-Mut4 maintained the bioactivities of wild-type TFPI, prolonged half-life in vivo simultaneously and were expected for better clinical value and therapeutic effect.

Keywords

TFPI - half-life - mutants - pharmacokinetics

• References

• 1 Bajaj MS, Birktoft JJ, Steer SA. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 959-72.
• 2 Park CT, Creasey AA, Wright SD. Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14. Blood 1997; 89: 4268-74.
• 3 Warshawsky I, Bu G, Mast A. et al. The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 1995; 95: 1773-81.
• 4 Matyal R, Vin Y, Delude RL. Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock. Intensive Care Med 2001; 27: 1274-80.
• 5 Opal SM, Palardy JE, Parejo NA. et al. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 2001; 29: 13-7.
• 6 Abraham E, Reinhart K, Svoboda P. et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001; 29: 2081-9.
• 7 Palmier MO, Hall LJ, Reisch CM. et al. Clearance of recombinant tissue factor pathway inhibitor (TFPI) in rabbits. Thromb Haemost 1992; 68: 33-6.
• 8 Diaz-Collier JA, Palmier MO, Kretzmer KK. et al. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli. Thromb Haemost 1994; 71: 339-46.
• 9 Yang Yinke, He Xiaofan, Li Juncheng. et al. Preparation and characterization of monoclonal antibody against recombinant human tissue factor pathway inhibitor. Chin Med J 1998; 111: 718-21.
• 10 Holst J, Lindblad B, Westerlund G. et al. Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor. Thromb Res 1996; 81: 461-70.
• 11 Kamikubo Y, Hamuro T, Matsuda J. et al. The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (h-rTFPI) in rabbits: a complex formation of h- rTFPI with factor Xa promotes a clearance rate of h-rTFPI. Thromb Res 1996; 83: 161-73.
• 12 Abraham E, Reinhart K, Opal S. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003; 290: 238-47.
• 13 Angus DC, Crowther MA. Unraveling severe sepsis: why did OPTIMIST fail and what's next?. JAMA 2003; 290: 256-8.
• 14 Narita M, Bu G, Olins GM. et al. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem 1995; 270: 24800-4.
• 15 Warshawsky I, Broze Jr GJ, Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci 1994; 91: 6664-8.
• 16 Warshawsky I, Herz J, Broze GJ. et al. The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis. J Biol Chem 1996; 271: 25873-9.
• 17 Neels JG, van Den Berg BM, Lookene A. et al. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J Biol Chem 1999; 274: 31305-11.
• 18 Iakhiaev A, Pendurthi UR, Voigt J. et al. Catabolism of factor VIIa bound to tissue factor in fibroblasts in the presence and absence of tissue factor pathway inhibitor. J Biol Chem 1999; 274: 36995-7003.
• 19 Hamik A, Setiadi H, Bu G. et al. Down-regulation of monocyte tissue factor mediated by tissue factor pathway inhibitor and the low density lipoprotein receptorrelated protein. J Biol Chem 1999; 274: 4962-9.
• 20 Higuchi DA, Wun TC, Likert KM. et al. The effect of leukocyte elastase on tissue factor pathway inhibitor. Blood 1992; 79: 1712-9.
• 21 Petersen LC, Bjorn SE, Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1992; 67: 537-41.
• 22 Ohkura N, Enjyoji K, Kamikubo Y. et al. A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood 1997; 90: 1883-92.
• 23 Salemink I, Franssen J, Willems GM. et al. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity. Thromb Haemost 1998; 80: 273-80.
• 24 Li A, Wun TC. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb Haemost 1998; 80: 423-7.
• 25 Stalboerger PG, Panetta CJ, Simari RD. et al. Plasmin proteolysis of endothelial cell and vessel wall associated tissue factor pathway inhibitor. Thromb Haemost 2001; 86: 923-8.
• 26 Belaaouaj AA, Li A, Wun TC. et al. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem 2000; 275: 27123-8.
• 27 Cunningham AC, Hasty KA, Enghild JJ. et al. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Biochem J 2002; 367: 451-8.